Join        Login             Stock Quote

Aegerion's (AEGR) JUXTAPID Capsules Wins FDA Approval

 December 24, 2012 08:09 AM

(By Balachander) Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) said the U.S. health regulators have cleared its drug to treat a rare genetic disease that results in extreme elevation of blood cholesterol levels.

The U.S. Food & Drug Administration (FDA) has approved Aegerion's first product JUXTAPID (lomitapide) capsules for the treatment of a rare genetic disease that impairs the function of the receptor responsible for removing bad cholesterol from the body.

The FDA's approval is based on Aegerion's late-stage study which evaluated the safety and effectiveness of the medicine to reduce LDL-C levels in 29 adult patients with homozygous familial hypercholesterolemia (HoFH).

[Related -Analysts' Rating And Target Changes: AEGR, CHMT, DPZ, KAR, MRVL]

Because of the risk of liver toxicity, JUXTAPID is available only through a restricted program called the JUXTAPID Risk Evaluation and Mitigation Strategy (REMS) Program, Cambridge, Massachusetts-based Aegerion noted.

The company also said safety and effectiveness of JUXTAPID have not been established in patients with hypercholesterolemia who do not have HoFH.

HoFH patients often develop premature and progressive atherosclerosis, a narrowing or blocking of the arteries.

The stock, which has been trading in the 52-week range of $11.75 to $25.74, closed at $25.71 on Friday.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageThe S&P 500’s Worrisome Downturn In Drawdown

Last Friday I reviewed some of the bearish signals that were casting dark shadows across the US stock read on...

article imageADP: Private-Sector Employment Rises A Solid 200k In September

The pace of growth for private-sector employment picked up in September, according to this morning’s ADP read on...

article imageTreasury Market’s Inflation Expectations Tumble

The odds for a Fed rate hike are falling like a stone, or so it appears based on the implied inflation read on...

article imageEmerging Market Stocks: Last Week’s Red-Ink Leader

Value investors on the lookout for bargains have recently been eyeing up the battered corner of emerging read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.